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DEPT. OF PHARMACOLOGY
DIRECTOR, INSTITUTE FOR TRANSLATIONAL MEDICINE & THERAPEUTICS
UNIVERSITY OF PENNSYLVANIA

The relative strengths and weakness of academia and industry in the skills
necessary to bring a molecule forward to an approved drug are widely
appreciated. Indeed, the efficiency of moving to a modular approach to drug
discovery and development—with modules drawn at different stages from
diverse sectors and geographies—has been realized in the altruistic sector.
However, conversion of this approach to the for–profit sector requires a
revision of our thinking on intellectual property (IP).
The potential value of too many molecules remains locked in company
freezers, while exploitation of biological insights in academia is classically
limited by the lack of tool compounds and of translational infrastructure to
convert such leads into approved drugs. Segregating these opportunities from
each other are unrealistic expectations of IP rewards by both academia and
industry, and an outmoded and inefficient approach to IP by both parties. While
some progress has been made with respect to academic infrastructure via
clinical and translational science awards; and, industry has begun to make
widespread but essentially limited deals with universities, it is worth
considering the fundamentals of IP.
Despite the odds of a new molecular entity becoming an approved drug
being extremely long, the dominant IP is vested in chemical composition of
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matter. In the era of large vertically integrated companies—now on the wane—
this did not really matter. The chemist, the expert in model systems and the
clinical trialist all worked for the sponsoring company and all would profit via
its stock shares if the drug was approved. In an era of modular drug discovery
and development, the trick will be to engage the best investigators at various
stages in the process, despite them working in a different public or private entity
than the originator of the chemical matter in question. Provision of the funds
to do their bit of the research will be insufficient; if they are best in brand they
will have plenty of resources to conduct the research that is their own priority.
Rather, they need to be incentivized by a piece of the action—some of the profit
derived from an approved drug.
As suggested recently,6 one approach would be to model prospectively the
hurdles in the process and to apportion value—in terms of a share in the
profits—to overcoming them on the way to drug approval. This has the
attraction of postponing the statement of value until it is actually realized. It
shifts the dominant IP from an entity with perhaps a 1:40,000 chance of having
commercial value to something that actually has value. Of course, real life will
depart from the prospective model, but the model can be adjusted in Bayesian
fashion as the process proceeds, so that at its conclusion, the model will
recapitulate the relative challenge of the hurdles along the way and apportion
value appropriately to their being overcome. This approach requires an initial
pot of money—potentially from diverse funders who may set the “grand
challenge”—and prospective agreement on the part of contributions to their
reward being subject to the modeling exercise.
We are used to modeling—3d structures, pharmacokinetics, and market
value—at many stages of drug development; perhaps we should extend it to the
domain of IP.
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